This move towards localizing the manufacturing of Sanofi's Clexane adapts to changing market dynamics and enhancement of industrial innovative technologies
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane. (Credit: PRNewsfoto/ Minapharm Pharmaceuticals)
Sanofi and Minapharm announce the signing of an exclusive Manufacturing and Supply Agreement for the localization of the full range of its flagship market leader product, Clexane.
The agreement between Sanofi, a global pharmaceutical company and Egypt’s Minapharm, a regional Biotech company with wholly owned subsidiaries in Cairo and Berlin, boosts Egypt’s national localization strategy of biopharmaceutical manufacturing.
This move towards localizing the manufacturing of Sanofi’s Clexane adapts to changing market dynamics and enhancement of industrial innovative technologies.
The manufacturing of Clexane will take place in Minapharm’s second new state-of-the-art biopharmaceutical facility in Egypt dedicated to research, development and manufacture of complex bioengineered proteins.
In the presence of Sanofi Senior Management, Christelle Saghbini, Head of Innovate to Grow Markets, Jeremy Goldnadel, Cluster Head International General Medicine and Ahmed Youssef, Head of Manufacturing site, the agreement between the 2 companies has been signed by Dr. Ahmed Raouf, Managing director & Chairperson on behalf of Sanofi Egypt, and by Dr. Wafik Bardissi, Chairman and CEO of Minapharm on behalf of Minapharm.
Dr. Ahmed Raouf, Managing Director and Chairperson of Sanofi Egypt said:” This agreement affirms Sanofi Egypt’s pledge to support the localization plan of pharmaceutical and biological industries in Egypt by transfer of advanced manufacturing technology in cooperation with distinctive industry partners. This event comes as a continuation of efforts to provide essential and modern treatments to the Egyptian patient.”
Dr. Wafik Bardissi, Chairman and CEO of Minapharm said: “This partnership with Sanofi corroborates the common national health policy directives with the commitment of both parties to ensure elevated patient access to essential complex biologics. It further complements the local, regional and global technology contribution of Minapharm and its European subsidiaries to the world’s bio-industry.”
Source: Company Press Release